HUTCHMED (China) Limited (HCM) RNS Announcements

Add to Alert list
Date Time Source Announcement
14 Sep 2022 11:00 AM
RNS
Share Option Scheme and Long Term Incentive Plan
08 Sep 2022 07:00 AM
RNS
FRESCO-2 Colorectal Cancer MRCT Data Highlights
23 Aug 2022 10:00 AM
RNS
Holding(s) in Company
23 Aug 2022 09:30 AM
RNS
HUTCHMED To Present FRESCO-2 Data at ESMO 2022
09 Aug 2022 09:30 AM
RNS
First Participant in Phase I Trial of IMG-004
08 Aug 2022 09:30 AM
RNS
Preliminary results from SAVANNAH Phase 2 Trial
08 Aug 2022 07:00 AM
RNS
FRESCO-2 Study Has Met Primary Endpoint
01 Aug 2022 12:04 PM
RNS
Interim Results and Business Updates
01 Aug 2022 07:00 AM
RNS
HUTCHMED Initiates Bridging Study of Tazemetostat
15 Jul 2022 09:30 AM
RNS
HUTCHMED Initiates Phase I Trial of HMPL-A83
13 Jul 2022 07:00 AM
RNS
Results of SAVANNAH Global Phase II Trial at WCLC
06 Jul 2022 07:00 AM
RNS
First Participants in Phase I Trial of IMG-007
30 Jun 2022 09:30 AM
RNS
Total Voting Rights
29 Jun 2022 09:30 AM
RNS
Blocklisting Six Monthly Return
27 Jun 2022 09:30 AM
RNS
HUTCHMED to Announce 2022 Half-Year Results
01 Jun 2022 09:30 AM
RNS
TAZVERIK® Approved in Hainan Pilot Zone
24 May 2022 11:00 AM
RNS
LTIP and Share Options
16 May 2022 12:00 PM
RNS
Appointment of Non-Executive Director
03 May 2022 07:00 AM
RNS
HUTCHMED Receives CRL from the US FDA
27 Apr 2022 02:30 PM
RNS
Annual General Meeting Poll Results
21 Apr 2022 09:30 AM
RNS
Vesting of awards under Long Term Incentive Plan
31 Mar 2022 07:00 AM
RNS
Update on Status under HFCAA
23 Mar 2022 08:30 AM
RNS
2021 Annual Report and Notice of AGM
11 Mar 2022 09:00 AM
RNS
Update on Status under HFCAA
09 Mar 2022 08:30 AM
RNS
Vesting of awards under Long Term Incentive Plan
07 Mar 2022 07:00 AM
RNS
HUTCHMED Receives $15m Milestone from AstraZeneca
03 Mar 2022 03:30 PM
RNS
Publication of Form 20-F
03 Mar 2022 12:30 PM
RNS
Retirement of CEO and appointment of new CEO
03 Mar 2022 12:00 PM
RNS
Full Year Results and Business Updates
01 Mar 2022 08:30 AM
RNS
Approval to Commercialize ELUNATE® in Macau
07 Feb 2022 08:30 AM
RNS
HUTCHMED to Announce 2021 Final Results
04 Feb 2022 09:30 AM
RNS
Phase Ib/II Combination Study of HMPL-453
20 Jan 2022 07:00 AM
RNS
HUTCHMED Initiates Phase I Trial of HMPL-653
19 Jan 2022 07:00 AM
RNS
HUTCHMED Data at ASCO GI Cancers Symposium
17 Jan 2022 09:00 AM
RNS
Holding(s) in Company
12 Jan 2022 11:00 AM
RNS
Breakthrough Therapy Designation for HMPL-523
10 Jan 2022 07:00 AM
RNS
HUTCHMED Initiates Phase I Study of HMPL-760
31 Dec 2021 07:00 AM
RNS
Blocklisting Six Monthly Return
31 Dec 2021 07:00 AM
RNS
Total Voting Rights
20 Dec 2021 07:00 AM
RNS
HUTCHMED Included in FTSE Russell Indexes
15 Dec 2021 09:45 AM
RNS
Grant of Share Options and Awards under LTIP
14 Dec 2021 07:00 AM
RNS
HMPL-523 Clinical Data Presented at ASH
10 Dec 2021 10:00 AM
RNS
HUTCHMED Presents Data at ESMO Immuno-Oncology '21
06 Dec 2021 07:00 AM
RNS
HUTCHMED Completes Planned Enrollment of FRESCO-2
03 Dec 2021 07:00 AM
RNS
Updated NRDL to include ELUNATE and SULANDA
30 Nov 2021 08:30 AM
RNS
Total Voting Rights
24 Nov 2021 07:00 AM
RNS
HUTCHMED and AZ Initiate SACHI Phase 3 Trial
08 Nov 2021 07:00 AM
RNS
HUTCHMED to Present Clinical Data at ASH
01 Nov 2021 07:00 AM
RNS
HUTCHMED and AZ Initiate SAMETA Global P3 Trial
29 Oct 2021 09:30 AM
RNS
Total Voting Rights

Hutchmed China  Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) is headquartered in Hong Kong and markets its products worldwide.

It was founded in 2000 and listed in London in 2018 under the ticker HCM. 

UK 100

Latest directors dealings